{"generic":"Vinflunine Ditartrate","drugs":["Vinflunine Ditartrate"],"mono":{"0":{"id":"jxw9s0","title":"Generic Names","mono":"Vinflunine Ditartrate"},"1":{"id":"jxw9s1","title":"Dosing and Indications","sub":{"0":{"id":"jxw9s1b4","title":"Adult Dosing","mono":"<ul><li>vinflunine ditartrate has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>contraindicated in patients with baseline absolute neutrophil count (ANC) less than 1500\/mm(3) or platelets less than 100,000\/mm(3); for subsequent cycles, vinflunine is contraindicated in patients with baseline ANC less than 1000\/mm(3) or platelets less than 100,000\/mm(3)<\/li><li><b>Transitional cell carcinoma of the urinary tract, Advanced or metastatic, after failure of platinum-containing regimen:<\/b> 320 mg\/m(2) IV over 20 minutes every 3 weeks (European Medicines Agency-approved dosing)<\/li><\/ul>"},"2":{"id":"jxw9s1b6","title":"Dose Adjustments","mono":"<ul><li><b>cardiac ischemia, during therapy in patients with a history of myocardial infarction or angina pectoris:<\/b> discontinue therapy<\/li><li><b>geriatric:<\/b> if younger than 75 years, no dose adjustment required; if 75 years to younger than 80 years, reduce dose to 280 mg\/m(2) IV every 3 weeks; if 80 years or older, reduce dose to 250 mg\/m(2) IV every 3 weeks<\/li><li><b>hematologic toxicity:<\/b> neutropenia (absolute neutrophil count (ANC) less than 1000\/mm(3)) or thrombocytopenia (platelets less than 100,000\/mm(3), delay therapy until recovery, discontinue if recovery not attained in 2 weeks; adjust dose with grade 4 neutropenia for longer than 7 days or febrile neutropenia<\/li><li><b>hematologic toxicity:<\/b> neutropenia grade 4 (absolute neutrophil count (ANC) less than 500\/mm(3)) for longer than 7 days, or febrile neutropenia (ANC less than 1000\/mm(3) and fever 38.5 degrees C or greater); if initial dose 320 mg\/m(2), reduce to 280 mg\/m(2) for first event, reduce to 250 mg\/m(2) for second consecutive event, discontinue for third consecutive event; if initial dose 280 mg\/m(2), reduce to 250 mg\/m(2) for first event, discontinue for second consecutive event; if initial dose 250 mg\/m(2), reduce to 225 mg\/m(2) for first event, discontinue for second consecutive event<\/li><li><b>hepatic impairment:<\/b> no dose adjustment required if prothrombin time greater than 70% of normal and with at least 1 of: (bilirubin range, greater than ULN to less than or equal to 1.5 times ULN, transaminases range, greater than 1.5 times ULN to less than or equal to 2.5 times ULN, gamma glutamyl transferase range from greater than ULN to less than or equal to 5 times ULN); or transaminases less than or equal to 2.5 times ULN (or less than 5 times ULN only in cases of liver metastases)<\/li><li><b>hepatic impairment:<\/b> if mild (Child-Pugh grade A), or prothrombin time greater than or equal to 60% normal and bilirubin greater than 1.5 times ULN to less than or equal to 3 times ULN and either transaminases greater than the ULN or gamma glutamyl transferase greater than 5 times ULN, reduce to 250 mg\/m(2) IV every 3 weeks<\/li><li><b>hepatic impairment:<\/b> if moderate impairment (Child-Pugh grade B), or prothrombin time greater than or equal to 50% normal, bilirubin greater than 3 times ULN, and transaminases and gamma glutamyl transferase greater than the ULN, reduce to 200 mg\/m(2) IV every 3 weeks<\/li><li><b>mucositis or constipation grade 2 for 5 days or more:<\/b> if initial dose 320 mg\/m(2), reduce to 280 mg\/m(2) for first event; reduce to 250 mg\/m(2) for second consecutive event; discontinue for third consecutive event; if initial dose 280 mg\/m(2), reduce to 250 mg\/m(2) for first event; discontinue for second consecutive event; if initial dose 250 mg\/m(2), reduce to 225 mg\/m(2) for first event, discontinue for second consecutive event<\/li><li>nonhematologic toxicity, grade 3 or higher (except nausea\/vomiting); if initial dose 320 mg\/m(2), reduce to 280 mg\/m(2) for first event; reduce to 250 mg\/m(2) for second consecutive event; discontinue for third consecutive event; if initial dose 280 mg\/m(2), reduce to 250 mg\/m(2) for first event; discontinue for second consecutive event; if initial dose 250 mg\/m(2), reduce to 225 mg\/m(2) for first event, discontinue for second consecutive event<\/li><li><b>organ toxicity, moderate, severe, or life-threatening:<\/b> delay until recovery to mild or none; adjust dose if necessary; discontinue if recovery not attained in 2 weeks<\/li><li><b>renal impairment:<\/b> (CrCl greater than 60 mL\/min), no dose adjustment required<\/li><li><b>renal impairment:<\/b> moderate (CrCl, 40 mL\/min or greater to less than or equal to 60 mL\/min), reduce to 280 mg\/m(2) IV every 3 weeks<\/li><li><b>renal impairment:<\/b> severe (CrCl, greater than or equal to 20 mL\/min to less than 40 mL\/min), reduce to 250 mg\/m(2) IV once every 3 weeks<\/li><li><b>WHO or Eastern Cooperative Oncology Group performance status of 1 or 0 with prior pelvic irradiation:<\/b> initiate at 280 mg\/m(2); increase to 320 mg\/m(2) IV every 3 weeks for subsequent cycles if hematologic toxicity absent in first cycle<\/li><\/ul>"},"3":{"id":"jxw9s1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Transitional cell carcinoma of the urinary tract, Advanced or metastatic, after failure of platinum-containing regimen<br\/>"}}},"3":{"id":"jxw9s3","title":"Contraindications\/Warnings","sub":[{"id":"jxw9s3b9","title":"Contraindications","mono":"<ul><li>Baseline absolute neutrophil count less than 1500\/mm(3) for initial infusion or less than 1000 mm(3) for subsequent infusions<\/li><li>Platelet count less than 100,000\/mm(3)<\/li><li>Breastfeeding<\/li><li>Hypersensitivity to vinflunine, any component of the product, or other vinca alkaloids<\/li><li>Recent (within 2 weeks) or active severe infection<\/li><\/ul>"},{"id":"jxw9s3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- QT-interval prolongation has been reported and may lead to an increased risk for ventricular arrhythmias<\/li><li>--  Use with caution in patients with proarrhythmic risk factors (eg, congestive heart failure, known history of QT-interval prolongation, hypokalemia)<\/li><li>-- Cardiac ischemia may occur; particularly among patients with underlying cardiac disease (history of myocardial infarction\/ischemia or angina pectoris); monitoring recommended; therapy discontinuation should be considered if cardiac ischemia develops<\/li><li>Endocrine and Metabolic:<\/li><li>-- Severe hyponatremia, including SIADH, has been reported; monitoring recommended<\/li><li>Gastrointestinal:<\/li><li>-- Constipation, including cases requiring manual evacuation or enema have been reported, with an increased risk with concomitant opiates, peritoneal carcinomas, abdominal masses, and prior major abdominal surgery; dosage adjustment or discontinuation may be necessary<\/li><li>-- Mucositis may occur; dosage adjustment or discontinuation may be necessary<\/li><li>Hematologic:<\/li><li>-- Hematologic toxicity, including neutropenia, leukopenia, anemia, and thrombocytopenia, occurs frequently; monitoring recommended dose reduction, interruption, or discontinuation may be necessary<\/li><li>Hepatic:<\/li><li>-- Hepatic impairment; dosage adjustment necessary<\/li><li>Neurologic:<\/li><li>-- Posterior reversible encephalopathy syndrome has been reported; If suspected brain imaging recommended to confirm diagnosis, consider therapy discontinuation if neurological signs and symptoms develop<\/li><li>Renal:<\/li><li>-- Moderate or severe renal impairment; dosage adjustment necessary<\/li><li>Reproductive:<\/li><li>-- Pregnancy; use not recommended; effective contraception for both men and women is recommended during treatment and up to 3 months after last administration<\/li><li>Other:<\/li><li>-- Elderly, 75 years or older; dosage adjustment necessary<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use with other QT\/QTc interval-prolonging agents<\/li><li>-- Avoid concomitant use with potent inhibitors or inducers of CYP3A4<\/li><\/ul>"},{"id":"jxw9s3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxw9s3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"jxw9s4","title":"Drug Interactions","sub":[{"id":"jxw9s4b13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"jxw9s4b14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"}]},"5":{"id":"jxw9s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Injection site irritation, Venous (Grade 1, 22%; grade 2, 11%; grade 3, 0.8%)<\/li><li><b>Dermatologic:<\/b>Alopecia (All grades, 28.7%), Injection site reaction (All grades, 27.6%; grade 3 or 4, 0.4%)<\/li><li><b>Endocrine metabolic:<\/b>Hyponatremia (All grades, 39.8%; grade 3 or 4, 11.7%), Weight decreased (All grades, 24%; grade 3 or 4, 0.4%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (All grades, 21.6%; grade 3 or 4, 4.7%), Constipation (All grades, 54.9%; grade 3 or 4, 15.3%), Diarrhea (All grades, 12.9%; grade 3 or 4, 0.9%), Loss of appetite (All grades, 34.4%; grade 3 or 4, 2.7%), Nausea (All grades, 40.9%; grade 3 or 4, 2.9%), Stomatitis (All grades, 26.9%; grade 3 or 4, 2.7%), Vomiting (All grades, 27.3%; grade 3 or 4, 2.9%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (92.8%), Leukopenia, All grades (84.5%), Neutropenia, All grades (All grades, 79.6%), Thrombocytopenia, All grades (53.5%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (All grades, 8%; grade 3 or 4, 0.7%), Myalgia (All grades, 16.4%; grade 3 or 4, 3.1%)<\/li><li><b>Neurologic:<\/b>Asthenia<\/li><li><b>Other:<\/b>Dehydration (All grades, 4.4%; grade 3 or 4, 2%), Fatigue (All grades, 55.3%; grade 3 or 4, 15.8%), Fever (All grades, 10.9%; grade 3 or 4, 0.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction (Grade 3 or 4, 0.2%), Myocardial ischemia (Grade 3 or 4, 0.7%), Prolonged QT interval, Syncope (Grade 3 or 4, 1.1%), Venous thrombosis (All grades, 3.3%; grade 3 or 4, 0.4%)<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction (All grades, 2.7%; grade 3 or 4, 2.2%)<\/li><li><b>Hematologic:<\/b>Anemia, Grades 3 or 4 (17.3%), Febrile neutropenia, Grade 3 or 4 (6.7%), Leukopenia, Grade 3 or 4 (45.2%), Neutropenia, Grade 3 or 4 (54.6%), Thrombocytopenia, Grade 3 or 4 (4.9%)<\/li><li><b>Neurologic:<\/b>Posterior reversible encephalopathy syndrome<\/li><li><b>Renal:<\/b>Renal failure (Grade 3 or 4, 0.2%)<\/li><li><b>Respiratory:<\/b>Acute respiratory distress syndrome (Grade 3 or 4, 0.2%)<\/li><li><b>Other:<\/b>Infectious disease, Neutropenic (Grade 3 or 4, 3.8%), Neutropenic sepsis (Gade 3 or 4, 0.2%)<\/li><\/ul>"},"6":{"id":"jxw9s6","title":"Drug Name Info","sub":{"2":{"id":"jxw9s6b19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Mitotic Inhibitor<\/li><\/ul>"},"3":{"id":"jxw9s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxw9s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IV use only; intrathecal administration may be fatal; do not administer as rapid IV bolus<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>For single-use only<\/li><li>Dilute appropriate dose in 100 mL NS or D5W.<\/li><li>Use immediately after dilution and protect diluted solution from light until administration.<\/li><li>If protected from light, the diluted solution in a polyethylene or polyvinylchloride infusion bag is stable for up to 6 days refrigerated (2 to 8 degrees C) or for up to 24 hours at room temperature (25 degrees C).<\/li><li>If exposed to light in a polyethylene or polyvinylchloride infusion set, the diluted solution is stable for up to 1 hour at room temperature (25 degrees C).<\/li><li>Administer through central or peripheral line, avoiding hand dorsum veins and those close to joints; venous irritation may occur with peripheral administration.<\/li><li>Flush vein with 250 mL NS or D5W solution for infusion (one-half of a 500-mL bag) at free-flowing rate prior to administration.<\/li><li>The diluted vinflunine solution should be piggy-backed to the side injection port closest to 500-mL bag for further dilution.<\/li><li>Infuse IV over 20 minutes.<\/li><li>After administration, flush with remaining 250 mL NS or D5W (or at least equal volume) at a rate of 300 mL\/hr.<\/li><li>Laxatives and dietary modifications, including oral hydration, should be administered from days 1 to 5 or 7 after each infusion.<\/li><\/ul><\/li><\/ul>"}}}